Synlab Group Selects Bruker´s MALDI Biotyper System for Mass Spectrometry-based Molecular Microbial Identification
December 03 2009 - 12:00AM
Business Wire
At the KMIS meeting (Klinisch-Mikrobiologisch-Infektiologisches
Symposium) on Dec. 3-5, 2009 in Berlin, Bruker Daltonics announces
a framework agreement with Synlab (www.synlab.de) concerning
molecular microbial identification based on MALDI-TOF mass
spectrometry. Synlab is a European private diagnostic laboratory
association, and Bruker Daltonics is the worldwide leading provider
of mass spectrometry-based microorganism identification solutions.
Synlab currently has more than 70 diagnostic laboratories in
Germany and other European countries.
Synlab and Bruker have concluded a long-term partnership
agreement in order to equip the laboratories of the Synlab
association exclusively with the MALDI Biotyper system for
fast and reliable molecular microbial identification. The MALDI
Biotyper is currently already in routine use in Synlab’s
clinical microbiology centers in Trier, Weiden and Dachau in
Germany. Moreover, Bruker and Synlab intend to further enlarge and
refine the MALDI Biotyper reference library using well
defined clinical isolates from the daily microbiology routine work
of the Synlab laboratories.
The MALDI Biotyper is integrated into the Synlab
laboratories’ microbiology workflow, combining fast molecular
identification with conventional antibiotic susceptibility testing
(AST). The MALDI Biotyper reports the identification results
into the existing laboratory information systems (LIS). Integration
with LIS MCS (www.mcs-ag.com), Medat (www.medat.de) and
Vision4health (www.vision4health.com) has already been established
for Synlab, while integration with other LIS providers is also
possible.
Dr. Ulrich Knipp, Technical Head of Microbiology at Synlab in
Trier, commented: “After evaluating the MALDI Biotyper very
thoroughly within the Synlab group, we are convinced that Bruker
Daltonics is the most reliable partner for microbial identification
based on mass spectrometry, and is providing outstanding
microbiological service and support. Bruker Daltonics is fully
established in the clinical microbiology market, and the MALDI
Biotyper fulfils our requirements for reliability and
robustness. The MALDI Biotyper represents a clear milestone
substantiating our high quality molecular microbiology
diagnostics.”
Dr. Guido Mix, Director of Microbiology at Bruker Daltonics,
added: “We are very pleased that our MALDI Biotyper fulfils
the high demands of leading clinical laboratories like Synlab. Our
framework contract with Synlab validates our efforts to provide
comprehensive service and applications support to our customers by
our dedicated microbiologists, fully developed technicians network
and dedicated IT specialists for integration into various
laboratory information systems (LIS).”
About the Bruker MALDI Biotyper
Bruker’s dedicated MALDI Biotyper solution
(www.bdal.com/maldibiotyper) enables molecular identification, and
taxonomical classification or dereplication of microorganisms like
bacteria, yeasts and fungi. Classification and identification of
microorganisms is achieved reliably and quickly using proteomic
fingerprinting by high-throughput MALDI-TOF mass spectrometry.
Applications include clinical routine microbial identification,
environmental and pharmaceutical analysis, taxonomical research,
food and consumer product safety and quality control, as well as
marine microbiology. Bruker’s robust MALDI Biotyper method requires
minimal sample preparation efforts and offers low consumables cost
per sample. The MALDI Biotyper is available in a
research-use-only version, as well as in an IVD-CE version
according to EU directive EC/98/79 in certain European
countries.
ABOUT BRUKER CORPORATION (NASDAQ: BRKR)
Bruker is a leading provider of high-performance scientific
instruments and solutions for molecular and materials research, as
well as for industrial and applied analysis. For more information:
www.bruker.com
CAUTIONARY STATEMENT
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
as that term is defined in the Private Securities Litigation Reform
Act of 1995. Any forward-looking statements contained herein are
based on current expectations, but are subject to a number of risks
and uncertainties. The factors that could cause actual future
results to differ materially from current expectations include, but
are not limited to, risks and uncertainties relating to adverse
changes in conditions in the global economy and volatility in the
capital markets, the integration of businesses we have acquired or
may acquire in the future, changing technologies, product
development and market acceptance of our products, the cost and
pricing of our products, manufacturing, competition, dependence on
collaborative partners and key suppliers, capital spending and
government funding policies, changes in governmental regulations,
intellectual property rights, litigation, and exposure to foreign
currency fluctuations. These and other factors are identified and
described in more detail in our filings with the SEC, including,
without limitation, our annual report on Form 10-K for the year
ended December 31, 2008, our most recent quarterly reports on Form
10-Q and our current reports on Form 8-K. We disclaim any intent or
obligation to update these forward-looking statements other than as
required by law.
Photos/Multimedia Gallery Available:
http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6112266&lang=en
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024